Navigation Links
CryoCath Announces Fiscal 2008 Second Quarter Results
Date:5/12/2008

ements, see CryoCath's annual report available at http://www.sedar.com under the heading Risks and Uncertainties in the Management's Discussion and Analysis section.

Consolidated Balance Sheets (unaudited)

As at March 31 September 30

2008 2007

$ $

ASSETS

Current Assets

Cash and cash equivalents 8,488,607 9,139,844

Cash subject to restrictions 500,000 612,500

Short-term investments held-to-maturity 2,002,233 14,894,481

Accounts receivables 8,069,275 7,027,518

Investment tax credits receivable 765,610 296,840

Inventories 6,506,589 7,701,067

Prepaid expenses 519,230 1,143,381

-------------------------------------------------------------------------

Total current assets 26,851,544 40,815,631

Cash subject to restrictions 1,500,000 700,000

Balance of sale receivable 1,712,873 1,563,195

Consoles at customers' premises 1,426,380 1,475,631

Property, plant, and equipment 2,421,100 2,881,313

Intellectual property 2,904,771 2,876,325

-------------------------------------------------------------------------

36,816,668 50,312,095

-------------------------------------------------------------------------

-------------------------------------------------------------------------

LIABILITIES AND SHAREHOL
'/>"/>

SOURCE CryoCath Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. CryoCath to Hold Second Quarter 2008 Conference Call and Webcast
2. CryoCath Reports Data Presented at the 74th Annual Meeting of the German Cardiac Society
3. CryoCath Introduces Arctic Front in Australia
4. CryoCath Appoints New Chief Financial Officer
5. CryoCath Technologies notice of annual meeting
6. CryoCath Announces Fiscal 2008 First Quarter Results
7. CryoCath Provides Update on Patent Infringement Lawsuit
8. CryoCath to Hold First Quarter 2008 Conference Call and Webcast
9. CryoCath intends to contest patent infringement claim by CryoCor, Inc.
10. CryoCath announces 2007 fourth quarter and fiscal year end financial results
11. CryoCath to present at Piper Jaffray and BMO Healthcare conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)... WASHINGTON, Oct. 6 /PRNewswire-USNewswire/ -- ...nst several companies alleging that they,submitted...kbacks and the,establishment of sham durable medic...nt announced today. The companies are McKesson Cor...MediNet), GGNSC Holdings LLC,Golden Gate Ancillar...
(Date:10/6/2008)... A study led by researchers at the University of ...that use of oral Vitamin D supplements bolsters pr...n the skin, and may help prevent skin infections t...most common form of eczema. , The study led by ...and chief of the Division of Dermatology at the UC...
(Date:10/6/2008)... SAN DIEGO, Oct. 6 /PRNewswire/ -- Developed in... of Pacific Palisades, CA is introducing,Revolutio...y into the,Plastic Surgery office of Dr. Steve Lav... XS-300(TM), is the first of its kind, and is base...hnology combined with,innovative proprietary softw...
(Date:10/6/2008)... Vision Audio Inc. has an...deo game designed to help train children with auti...Se Off-Road is a fun, non-violent learning experie...participate in their enhanced sound-based therapy,...dio ( http://www.easecd.com ). , ...
Breaking Medicine News(10 mins):Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Oral vitamin D may help prevent some skin infections 2Health News:Plan Your Breasts in 3-D 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 2Health News:Vision Audio Inc. Announces New EASe Games Designed for Children with Autism 3
...alth System say the federal government could promo...ive manner that would ultimately save lives. They ...rt a Flu vaccination programme, //by direct advert...cal companies. They are hoping to target individu...
...BCC-5) had doctors, nurses, patients and advocates...ient care//. Breast cancer is the most common canc...l rates are improving. The event was conducted by...th each other. The European Breast Cancer Coalitio...
...becoming apparent to the Government Health officia...is now pulling up// its socks and gearing up to ta...s, or directly observed treatment, short-course, a...by the World Health Organization and its partners,...
... noted in Europe, following the reduction in numbe...hift of the media coverage // to other important s...ion of consumer fears about bird flu. Although p...resent a pathetic picture, the overall situation s...
Other Medicine News:Health News:Influenza Vaccination For The Elderly 2
(Date:10/7/2008)... 125 Patient, Prospective Randomized Placebo-Contr...Significant Improved Overall Survival., MOUNTAIN ...unoTherapeutics has now evaluated the mature Phase...ine candidate PROSTVAC(TM) that had been,obtained ...he National,Cancer Institute (NCI) in the US., Th...
(Date:10/7/2008)... CE IVD Menu Expanded to Eight On-Demand Tests fo... System, SUNNYVALE, Calif., Oct. 7 /PRNews...nounced the release of Xpert(TM) vanA/vanB as a Eu...ctive on In Vitro Diagnostic,Medical Devices. The ...genes, the genes most commonly associated with van...
(Date:10/6/2008)... PRINCETON, N.J., Oct. 6 /PRNewswire-FirstCall...hat Richard E.T. Smith, Ph.D., is joining the,Comp...rporate,Communications. Dr. Smith will be responsi...report directly to Chief Financial Officer Kurt,Le...esident and Senior Biotechnology,Analyst at JPMorg...
(Date:10/6/2008)... Novel technology opens the door to the unders...esity, diabetes, ageing and cancer, BILLERICA, Ma...day,announced the release of the first ever analyt...ochondrial oxygen consumption and cytoplasmic,glyc...ast 75 years tools,for measuring cellular bioenerg...
Breaking Medicine Technology:BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 2Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 3Cepheid Announces CE IVD Release of First On-Demand Test for van A/van B Genes Most Associated With Hospital-Acquired VRE Infection 4Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 2Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications 3Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 2Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics 3International Wound Care Experts Medline Announce Pressure Ulcer Prevention Consensus Paper 5447 1International Wound Care Experts Medline Announce Pressure Ulcer Prevention Consensus Paper 5447 2International Wound Care Experts Medline Announce Pressure Ulcer Prevention Consensus Paper 5447 3Embryonic pathway delivers stem cell traits 19491 1Embryonic pathway delivers stem cell traits 19491 2Embryonic pathway delivers stem cell traits 19491 3Embryonic pathway delivers stem cell traits 19491 4Nonin 28R 29 Medical Pioneers First Interoperable Wireless Fingertip Pulse Oximeter 19487 1Nonin 28R 29 Medical Pioneers First Interoperable Wireless Fingertip Pulse Oximeter 19487 2Bankers Life and Casualty Company Named Corporate Honoree at Alzheimers Association Chicago Rita Hayworth Gala 19482 1Bankers Life and Casualty Company Named Corporate Honoree at Alzheimers Association Chicago Rita Hayworth Gala 19482 2
...entation of Final Phase I Monthly Implant and Phas...une 11, 2007 /PRNewswire/ -- Debiopharm,Group (Deb...evelopment specialist in oncology and serious medi...io 9902 (formerly ZT-1) studies,for the treatment ...ociation International Conference on the Preventio...
... Reported at the Congress of the European Hematolo...re-FirstCall/ -- Favrille,Inc. , a biopharmaceuti...munotherapies for the treatment of cancer, announc...avId(R) in patients,with indolent B-cell non-Hodgk... Congress of the European Hematology Association i...
Other Medicine Technology:Clinical Update - Debio 9902 (ZT-1) for Alzheimer's Disease 2Clinical Update - Debio 9902 (ZT-1) for Alzheimer's Disease 3Favrille Announces Data From Phase 2 Clinical Trial of FavId for,Indolent B-Cell Non-Hodgkin's Lymphoma in Europe 2Favrille Announces Data From Phase 2 Clinical Trial of FavId for,Indolent B-Cell Non-Hodgkin's Lymphoma in Europe 3
Features soft, low friction sheath that extends beyond the tip.
Designed to retain the desired curve during oral intubation.
Facilitates intubation of tracheal tubes.
SunGlide™ Stylette - Grey Child. Use in 4.0 to 7mm tubes. 25/box.
Medicine Products: